This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mo, H. Articles by Kempf, D. J. Search for Related Content PubMed PubMed Citation Articles by Mo, H. Articles by Kempf, D. J.

Selection of Resistance in Protease Inhibitor-Experienced, Human Immunodeficiency Virus Type 1-Infected Subjects Failing Lopinavir- and Ritonavir-Based Therapy: Mutation Patterns and Baseline Correlates

Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois

Received 6 August 2004/ Accepted 25 October 2004

The selection of in vivo resistance to lopinavir was characterized by analyzing the longitudinal isolates from 54 protease inhibitor-experienced subjects who either experienced incomplete virologic response or viral rebound subsequent to initial response while on treatment with lopinavir-ritonavir in Phase II and III studies. The evolution of incremental resistance to lopinavir (emergence of new mutation[s] and/or at least a twofold increase in phenotypic resistance compared to baseline isolates) was highly dependent on the baseline phenotype and genotype. Among the subjects demonstrating evolution of lopinavir resistance, mutations at positions 82, 54, and 46 in human immunodeficiency virus protease emerged frequently, suggesting that these mutations are important for conferring high-level resistance. Less common mutations, such as L33F, I50V, and V32I together with I47V/A, were also selected; however, new mutations at positions 84, 90, and 71 were not observed. The emergence of incremental resistance contrasts greatly with the low incidence of resistance observed after initiating lopinavir-ritonavir therapy in antiretroviral-naive patients, suggesting that partial resistance accumulated during prior protease inhibitor therapy can compromise the genetic barrier to resistance to lopinavir-ritonavir. The emergence of incremental resistance was uncommon in subjects whose baseline isolates contained eight or more mutations associated with lopinavir resistance and/or displayed >60-fold-reduced susceptibility to lopinavir, providing insight into suitable upper genotypic and phenotypic breakpoints for lopinavir-ritonavir.

This article has been cited by other articles:

• Margerison, E. S., Maguire, M., Pillay, D., Cane, P., Elston, R. C. (2008). The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication. J Antimicrob Chemother 61: 786-791 [Abstract] [Full Text]  
• Lambert-Niclot, S., Flandre, P., Canestri, A., Peytavin, G., Blanc, C., Agher, R., Soulie, C., Wirden, M., Katlama, C., Calvez, V., Marcelin, A.-G. (2008). Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir. Antimicrob. Agents Chemother. 52: 491-496 [Abstract] [Full Text]  
• Masse, S., Lu, X., Dekhtyar, T., Lu, L., Koev, G., Gao, F., Mo, H., Kempf, D., Bernstein, B., Hanna, G. J., Molla, A. (2007). In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 2 with Decreased Susceptibility to Lopinavir. Antimicrob. Agents Chemother. 51: 3075-3080 [Abstract] [Full Text]  
• King, M. S., Rode, R., Cohen-Codar, I., Calvez, V., Marcelin, A.-G., Hanna, G. J., Kempf, D. J. (2007). Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients. Antimicrob. Agents Chemother. 51: 3067-3074 [Abstract] [Full Text]  
• Resino, S., Bellon, J. M., Munoz-Fernandez, M. A., on behalf of the Spanish Group of HIV Infection, (2006). Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. J Antimicrob Chemother 57: 579-582 [Full Text]  
• Jimenez, J. L., Resino, S., Martinez-Colom, A., Bellon, J. M., Angeles Munoz-Fernandez, M., on behalf of the Spanish Group of Paediatric HIV I, (2005). Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy. J Antimicrob Chemother 56: 1081-1086 [Abstract] [Full Text]  
• Kagan, R. M., Shenderovich, M. D., Heseltine, P. N.R., Ramnarayan, K. (2005). Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci. 14: 1870-1878 [Abstract] [Full Text]